TPP1
Basic information
Region (hg38): 11:6612768-6619448
Previous symbols: [ "CLN2", "SCAR7" ]
Links
Phenotypes
GenCC
Source:
- neuronal ceroid lipofuscinosis 2 (Definitive), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 2 (Definitive), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 2 (Strong), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 2 (Strong), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 2 (Supportive), mode of inheritance: AR
- autosomal recessive spinocerebellar ataxia 7 (Supportive), mode of inheritance: AR
- neuronal ceroid lipofuscinosis (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Ceroid lipofuscinosis, neuronal, 2; Spinocerebellar ataxia, autosomal recessive 7 | AR | Neurologic | The condition involves neurodevelopmental sequelae, and intraventricular administration of cerliponase alfa has been reported as showing neurological benefit | Musculoskeletal; Neurologic; Ophthalmologic | 5634370; 5795346; 4116925; 3146310; 7668319; 9295267; 9788728; 10330339; 12376936; 15965709; 17959406; 18684116; 20820830; 21990111; 22612257; 23266810; 23418007; 26224725; 29688815 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (77 variants)
- Neuronal ceroid lipofuscinosis 2 (28 variants)
- Neuronal ceroid lipofuscinosis (11 variants)
- Inborn genetic diseases (5 variants)
- Autosomal recessive spinocerebellar ataxia 7;Neuronal ceroid lipofuscinosis 2 (3 variants)
- Neuronal ceroid lipofuscinosis 2;Autosomal recessive spinocerebellar ataxia 7 (3 variants)
- TPP1-related disorder (2 variants)
- Autosomal recessive spinocerebellar ataxia 7 (2 variants)
- Angelman syndrome (1 variants)
- Abnormality of the nervous system (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TPP1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 252 | 256 | ||||
missense | 29 | 316 | 362 | |||
nonsense | 25 | 12 | 39 | |||
start loss | 2 | |||||
frameshift | 37 | 26 | 63 | |||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 24 | 34 | ||||
splice region | 1 | 1 | 16 | 44 | 2 | 64 |
non coding | 53 | 170 | 15 | 245 | ||
Total | 86 | 96 | 376 | 430 | 18 |
Highest pathogenic variant AF is 0.000486
Variants in TPP1
This is a list of pathogenic ClinVar variants found in the TPP1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-6612772-C-T | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 12, 2018) | ||
11-6612805-C-A | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 13, 2018) | ||
11-6612831-A-G | Neuronal Ceroid-Lipofuscinosis, Recessive | Uncertain significance (Jun 14, 2016) | ||
11-6612912-A-G | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 13, 2018) | ||
11-6612918-C-T | Neuronal ceroid lipofuscinosis 2 | Benign (Jan 13, 2018) | ||
11-6612958-G-A | Neuronal ceroid lipofuscinosis 2 | Benign (Jan 13, 2018) | ||
11-6612976-G-A | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 13, 2018) | ||
11-6612986-G-A | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 13, 2018) | ||
11-6613006-A-G | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 13, 2018) | ||
11-6613038-C-T | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 13, 2018) | ||
11-6613068-A-T | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 13, 2018) | ||
11-6613118-A-G | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 12, 2018) | ||
11-6613134-A-C | Neuronal Ceroid-Lipofuscinosis, Recessive | Uncertain significance (Jun 14, 2016) | ||
11-6613235-G-A | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 12, 2018) | ||
11-6613244-T-A | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 12, 2018) | ||
11-6613264-G-T | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 15, 2018) | ||
11-6613296-A-T | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 12, 2018) | ||
11-6613329-C-CA | Neuronal Ceroid-Lipofuscinosis, Recessive | Conflicting classifications of pathogenicity (Jul 01, 2023) | ||
11-6613428-C-G | Neuronal ceroid lipofuscinosis 2 | Benign (Jan 12, 2018) | ||
11-6613438-A-G | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Apr 27, 2017) | ||
11-6613546-A-G | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 13, 2018) | ||
11-6613560-G-C | Neuronal ceroid lipofuscinosis 2 | Likely benign (Jan 13, 2018) | ||
11-6613562-A-T | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 13, 2018) | ||
11-6613609-G-A | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 13, 2018) | ||
11-6613717-G-A | Neuronal ceroid lipofuscinosis 2 | Uncertain significance (Jan 12, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TPP1 | protein_coding | protein_coding | ENST00000299427 | 13 | 6693 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
6.26e-7 | 0.994 | 125536 | 0 | 212 | 125748 | 0.000843 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.221 | 321 | 310 | 1.04 | 0.0000179 | 3614 |
Missense in Polyphen | 107 | 120.1 | 0.89093 | 1425 | ||
Synonymous | -0.160 | 127 | 125 | 1.02 | 0.00000674 | 1190 |
Loss of Function | 2.48 | 15 | 29.5 | 0.508 | 0.00000148 | 309 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000759 | 0.000759 |
Ashkenazi Jewish | 0.000497 | 0.000496 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.000323 | 0.000323 |
European (Non-Finnish) | 0.00145 | 0.00145 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000131 | 0.000131 |
Other | 0.000815 | 0.000815 |
dbNSFP
Source:
- Function
- FUNCTION: Lysosomal serine protease with tripeptidyl-peptidase I activity. May act as a non-specific lysosomal peptidase which generates tripeptides from the breakdown products produced by lysosomal proteinases. Requires substrates with an unsubstituted N-terminus (By similarity). {ECO:0000250|UniProtKB:Q9EQV6}.;
- Disease
- DISEASE: Ceroid lipofuscinosis, neuronal, 2 (CLN2) [MIM:204500]: A form of neuronal ceroid lipofuscinosis. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment pattern seen most often in CLN2 consists of curvilinear profiles. {ECO:0000269|PubMed:10330339, ECO:0000269|PubMed:10665500, ECO:0000269|PubMed:11241479, ECO:0000269|PubMed:11339651, ECO:0000269|PubMed:11589012, ECO:0000269|PubMed:12376936, ECO:0000269|PubMed:12414822, ECO:0000269|PubMed:12698559, ECO:0000269|PubMed:14736728, ECO:0000269|PubMed:19201763, ECO:0000269|PubMed:20340139, ECO:0000269|PubMed:21990111, ECO:0000269|PubMed:22612257, ECO:0000269|PubMed:9295267}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spinocerebellar ataxia, autosomal recessive, 7 (SCAR7) [MIM:609270]: Spinocerebellar ataxia defines a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR7 patients show difficulty walking and writing, dysarthria, limb ataxia, and cerebellar atrophy. {ECO:0000269|PubMed:23418007}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Lysosome - Homo sapiens (human);XBP1(S) activates chaperone genes
(Consensus)
Recessive Scores
- pRec
- 0.280
Intolerance Scores
- loftool
- 0.115
- rvis_EVS
- 0.4
- rvis_percentile_EVS
- 76.41
Haploinsufficiency Scores
- pHI
- 0.143
- hipred
- Y
- hipred_score
- 0.694
- ghis
- 0.454
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.771
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tpp1
- Phenotype
- muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype;
Zebrafish Information Network
- Gene name
- tpp1
- Affected structure
- mandibular arch skeleton
- Phenotype tag
- abnormal
- Phenotype quality
- decreased size
Gene ontology
- Biological process
- proteolysis;lipid metabolic process;lysosome organization;nervous system development;central nervous system development;protein catabolic process;epithelial cell differentiation;IRE1-mediated unfolded protein response;peptide catabolic process;bone resorption;neuromuscular process controlling balance
- Cellular component
- lysosome;melanosome;lysosomal lumen;extracellular exosome
- Molecular function
- endopeptidase activity;serine-type endopeptidase activity;protein binding;peptidase activity;serine-type peptidase activity;tripeptidyl-peptidase activity;peptide binding;metal ion binding